COVID-19 infection in adults and adolescents who are 12 years and up and weighing at least 40 kg. Patients who do not need oxygen but are at greater risk of developing a severe form of COVID infection can benefit from this therapy.
According to a press statement issued by the firm earlier this month, Xevudy should be given within five days after the commencement of COVID-19 symptoms. As a result of a supply agreement negotiated previously with the UK government, UK patients who are at greater risk of serious COVID-19 issues may soon be able to get sotrovimab. This conditional marketing authorisation is valid in England, Scotland, and Wales. According to the press statement, the therapy can be delivered in Northern Ireland under rule 174 of the Human Medicines Regulations 2012.
According to the clinical experiments, the results have demonstrated that sotrovimab remarkably lowers hospitalization or death rate in high-risk adult outpatients suffering mild to moderate COVID-19 symptoms. Compared to the placebo group, a 79 percent decline in hospitalization rate for over 24 hours or mortality due to any cause by Day 29 was noticed. Sotrovimab has worked effectively in clinical experiments carried out thus far, and nearly 2% of cases reported hypersensitivity reactions as the most common side effects.
In the press statement issued by George Katzourakis, senior vice-president of GSK, Europe, he expressed optimism over the availability of the right treatments in the country. He said, “The conditional marketing authorization in Great Britain, coupled with the supply agreement, is a testament to the critical need to make sotrovimab available in the [United Kingdom] as the pandemic continues to progress. We believe it is important to ensure that we have treatments ready and available, especially early treatment options, for a broad group of patients at increased risk of progressing to severe COVID-19”.
In the press statement issued by George Scangos, CEO of Vir, he expressed confidence in the new treatment. He said, “We are pleased with the UK Government’s recognition of the role that monoclonal antibodies, [such as] sotrovimab, have to play in addressing this pandemic. With clinical data demonstrating a 79% reduction in hospitalizations for more than 24 hours or death in non-hospitalized patients, we are confident sotrovimab will continue to be a critical tool in the fight against COVID-19. We look forward to making sotrovimab available to the NHS [National Health Service] and patients in the UK and to continuing our efforts to increase access worldwide”.
